Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOICE: Tenofovir Gel and Oral PrEP for HIV Prevention
NCT00705679Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2009
- Primary completion
- Aug 2012
- Modality
- Implantable Devices, Transdermal Patches, Hydrogel Systems
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of tenofovir gel, tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus infection (HIV) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of HIV-1 Infections at 30 months, Incidence Rate of HIV-1 Infections at 30 months and 1 more. Started Aug 2009; status: completed.
02
Drugs
tenofovir geltenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00705679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705679.